Analyst Consensus ?
ConsensusBuy35 ratings
Bullish2777.1%
Neutral822.9%
Bearish00.0%
Welltower Inc. · WELL · FY2024 Q3 · Calendar Q4 2024
Welltower raises 2024 FFO outlook as senior housing accelerates
The quarter supports a constructive growth case: senior-housing operating momentum, acquisitions and platform initiatives are reinforcing earnings, but financing, capex and execution risks remain material.
Reported After market closeNYSEReal Estate
$171.01B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.11
Consensus $1.04
EPS surprise
+6.7%
Reported versus consensus
Reported revenue
$2.01B
Consensus $2.07B
Revenue surprise
-3.0%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+5.2%
Event window
SPY move
+0.2%
Same window
Abnormal move
+5.0%
Stock minus SPY
Volume
2.1×
Versus trailing sessions
Subsequent drift
+1.2%
Up to 20 sessions
WELLSPY benchmark
Ask FN2 about WELL FY2024 Q3
Transcript, numbers and history already loaded
Why did WELL rise 5.2% after beating EPS estimates in FY2024 Q3?What changed in WELL's guidance and outlook in FY2024 Q3?Give me the bull and bear case for WELL after FY2024 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, Welltower reported continued senior-housing acceleration, a first quarter with revenue above $2 billion, $6.1 billion of year-to-date investment activity and progress on its digital move-in platform. The company also maintained a deleveraging focus and raised full-year 2024 FFO guidance.
Guidance delta
Management raised full-year 2024 FFO guidance by $0.13 per share.
Key takeaways
- Senior housing same-store NOI grew 23% year over year, with occupancy up 310 basis points and margins expanding.
- Investment activity reached $6.1 billion year to date, including $2.15 billion closed in Q3 across 15 deals.
- Management is scaling its operating and technology platforms while targeting leverage below 4x net debt/EBITDA by year-end.
Management priorities
- Expand the operating and technology platforms across the senior-housing portfolio
- Pursue selective bolt-on acquisitions in senior housing and wellness
- Continue deleveraging while using data science to improve asset management
Follow WELL with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$240.61Current
$80Low
$186.68Average
$275High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 19, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Oct 13, 2026 |
| JP Morgan | Overweight | Neutral | Upgrade | Sep 24, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Sep 21, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Sep 2, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Sep 1, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 4, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 3, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 31, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 22, 2026 |
| UBS | Buy | Buy | Maintain | Jul 8, 2026 |
| Deutsche Bank | Buy | Buy | Maintain | Jul 1, 2026 |
| Jefferies | Buy | Buy | Maintain | May 13, 2026 |
| RBC Capital Mkts | Outperform | Sector Perform | Upgrade | Feb 28, 2025 |
| Wedbush | Outperform | Neutral | Upgrade | Feb 14, 2025 |
| Raymond James | Strong Buy | Outperform | Upgrade | Nov 9, 2023 |
| Baird | Neutral | Neutral | Maintain | Sep 14, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Apr 3, 2023 |
| Berenberg | Buy | Buy | Maintain | Aug 16, 2022 |
| SMBC Nikko | Neutral | Outperform | Downgrade | Aug 11, 2022 |
| BMO Capital | Outperform | Market Perform | Upgrade | Aug 26, 2021 |
| Wolfe Research | Outperform | Outperform | Maintain | Jun 15, 2021 |
| CapitalOne Southecoast | Overweight | Equal Weight | Upgrade | May 21, 2021 |
| B of A Securities | Buy | Neutral | Upgrade | Mar 30, 2021 |
| Stifel | Hold | Hold | Maintain | Sep 2, 2020 |
| Stifel Nicolaus | Buy | Buy | Maintain | Sep 3, 2019 |
| Hilliard Lyons | Neutral | Underperform | Upgrade | Apr 27, 2018 |
| Bank of America | Neutral | Neutral | Maintain | Mar 8, 2018 |
| SunTrust Robinson Humphrey | Hold | Buy | Downgrade | Jan 19, 2017 |
| Mitsubishi UFJ | Overweight | Neutral | Upgrade | Jan 5, 2017 |
| Stephens & Co. | Overweight | Overweight | Maintain | Sep 14, 2016 |
| BTIG Research | Neutral | Neutral | Maintain | Aug 25, 2016 |
| Canaccord Genuity | Buy | Buy | Maintain | Aug 15, 2016 |
| ISI Group | Buy | Buy | Maintain | Oct 6, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $240.61. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Analyst unavailable | $268 | $234.85 | +11.4% | Oct 19, 2026 |
| Barclays | Analyst unavailable | $246 | $230.29 | +2.2% | Oct 13, 2026 |
| Evercore ISI | James Kammert | $256 | $232.53 | +6.4% | Sep 21, 2026 |
| Jefferies | Analyst unavailable | $275 | $234.29 | +14.3% | Sep 15, 2026 |
| Scotiabank | Analyst unavailable | $251 | $238.78 | +4.3% | Sep 2, 2026 |
| Morgan Stanley | Ronald Kamdem | $251 | $236.31 | +4.3% | Sep 1, 2026 |
| Wells Fargo | John Kilichowski | $266 | $236.31 | +10.6% | Sep 1, 2026 |
| Barclays | Analyst unavailable | $259 | $237.98 | +7.6% | Aug 31, 2026 |
| KeyBanc | Analyst unavailable | $275 | $233.1 | +14.3% | Aug 4, 2026 |
| RBC Capital | Analyst unavailable | $260 | $234.83 | +8.1% | Aug 3, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $260 | $234.02 | +8.1% | Jul 31, 2026 |
| Evercore ISI | James Kammert | $260 | $236.72 | +8.1% | Jul 30, 2026 |
| Mizuho Securities | Analyst unavailable | $260 | $246.44 | +8.1% | Jul 22, 2026 |
| UBS | Michael Goldsmith | $271 | $237.19 | +12.6% | Jul 8, 2026 |
| Barclays | Analyst unavailable | $254 | $232.69 | +5.6% | Jul 7, 2026 |
| Raymond James | David Rodgers | $226 | $213.5 | -6.1% | Jun 16, 2026 |
| Mizuho Securities | Vikram Malhotra | $239 | $216.01 | -0.7% | May 22, 2026 |
| Scotiabank | Analyst unavailable | $248 | $217.16 | +3.1% | May 21, 2026 |
| Jefferies | Jonathan Petersen | $248 | $217.5 | +3.1% | May 12, 2026 |
| BMO Capital | Analyst unavailable | $245 | $216.27 | +1.8% | May 4, 2026 |
| RBC Capital | Analyst unavailable | $238 | $216.91 | -1.1% | May 4, 2026 |
| UBS | Analyst unavailable | $249 | $216.91 | +3.5% | May 4, 2026 |
| RBC Capital | Analyst unavailable | $230 | $208.56 | -4.4% | Feb 24, 2026 |
| KeyBanc | Analyst unavailable | $240 | $209.54 | -0.3% | Feb 24, 2026 |
| Morgan Stanley | Analyst unavailable | $215 | $212.63 | -10.6% | Feb 18, 2026 |
| UBS | Analyst unavailable | $240 | $208.75 | -0.3% | Feb 12, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $230 | $208.54 | -4.4% | Feb 12, 2026 |
| UBS | Michael Goldsmith | $228 | $185.65 | -5.2% | Jan 8, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $204 | $183 | -15.2% | Jan 5, 2026 |
| Jefferies | Analyst unavailable | $231 | $190.46 | -4.0% | Dec 15, 2025 |
| UBS | Analyst unavailable | $232 | $201.92 | -3.6% | Dec 4, 2025 |
| Wells Fargo | Analyst unavailable | $218 | $204.09 | -9.4% | Nov 25, 2025 |
| Morgan Stanley | Analyst unavailable | $200 | $196.9 | -16.9% | Nov 20, 2025 |
| Evercore ISI | Steve Sakwa | $208 | $184.35 | -13.6% | Nov 5, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $200 | $179.48 | -16.9% | Oct 31, 2025 |
| Loop Capital Markets | Viacheslav Obodnikov | $196 | $177.2 | -18.5% | Oct 29, 2025 |
| UBS | Michael Goldsmith | $203 | $179.7 | -15.6% | Oct 29, 2025 |
| Wells Fargo | Analyst unavailable | $200 | $177.71 | -16.9% | Oct 21, 2025 |
| National Bank | Analyst unavailable | $246 | $173.29 | +2.2% | Oct 17, 2025 |
| Scotiabank | Analyst unavailable | $182 | $175.04 | -24.4% | Oct 6, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $195 | $178.14 | -19.0% | Oct 1, 2025 |
| UBS | Michael Goldsmith | $195 | $166.53 | -19.0% | Sep 19, 2025 |
| Evercore ISI | Analyst unavailable | $183 | $169.13 | -23.9% | Sep 15, 2025 |
| Scotiabank | Nicholas Yulico | $181 | $166.83 | -24.8% | Aug 28, 2025 |
| RBC Capital | Analyst unavailable | $168 | $153.51 | -30.2% | Feb 28, 2025 |
| Scotiabank | Nicholas Yulico | $133 | $126.51 | -44.7% | Sep 23, 2024 |
| RBC Capital | Michael Carroll | $114 | $115.73 | -52.6% | Aug 9, 2024 |
| Evercore ISI | Steve Sakwa | $105 | $112.24 | -56.4% | Jul 30, 2024 |
| Griffin | Michael Griffin | $120 | $103.53 | -50.1% | Jun 10, 2024 |
| Scotiabank | Nicholas Yulico | $108 | $101.46 | -55.1% | May 16, 2024 |
| RBC Capital | Michael Carroll | $101 | $97.44 | -58.0% | May 7, 2024 |
| Wedbush | Richard Anderson | $100 | $96.08 | -58.4% | May 3, 2024 |
| Wedbush | Richard Anderson | $90 | $86.16 | -62.6% | Nov 7, 2023 |
| Griffin | Michael Griffin | $81 | $70.56 | -66.3% | Apr 5, 2023 |
| Raymond James | Analyst unavailable | $82 | $69.78 | -65.9% | Jan 9, 2023 |
| Raymond James | Analyst unavailable | $72 | $65.7 | -70.1% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $74 | $70.27 | -69.2% | Nov 15, 2022 |
| KeyBanc | Jordan Sadler | $80 | $58.6 | -66.8% | Oct 10, 2022 |
| SMBC Nikko | Richard Anderson | $84 | $83.31 | -65.1% | Aug 11, 2022 |
| Scotiabank | Nicholas Yulico | $110 | $96.98 | -54.3% | Apr 10, 2022 |
| Barclays | Steve Valiquette | $95 | $90.97 | -60.5% | Mar 14, 2022 |
| BMO Capital | Juan C. Sanabria | $105 | $83.28 | -56.4% | Feb 16, 2022 |
| Credit Suisse | Omotayo Okusanya | $92 | $84.05 | -61.8% | Feb 1, 2022 |
| Robert W. Baird | Dave Rodgers | $95 | $83.24 | -60.5% | Jan 26, 2022 |
| Deutsche Bank | Derek Johnston | $103 | $84.94 | -57.2% | Jan 3, 2022 |
| J.P. Morgan | Michael Mueller | $90 | $79.75 | -62.6% | Dec 20, 2021 |
| Stifel Nicolaus | Steve Manaker | $83 | $82.54 | -65.5% | Aug 12, 2021 |
| Wells Fargo | Todd Stender | $89 | $85.88 | -63.0% | Jul 23, 2021 |
| Jefferies | Jonathan Petersen | $78 | $86.7 | -67.6% | Jul 15, 2021 |
Track every rating change on WELL the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationWelltower Inc. (NYSE:WELL), an S&P 500 company based in Toledo, Ohio, is a leader in reshaping healthcare infrastructure. This Real Estate Investment Trust (REIT) strategically collaborates with premier operators in seniors housing, post-acute care, and health systems. Their core mission is to finance the vital property assets required to expand innovative care delivery models, thereby enhancing overall public wellness and healthcare experiences. Welltower's portfolio encompasses a variety of properties, including seniors housing, post-acute communities, and outpatient medical facilities, all situated primarily within key, rapidly growing markets across the United States, Canada, and the United Kingdom.
Historical context
All WELL earningsReal Estate peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RITM-PD Rithm Capital Corp. | FY2026 Q3 · Calendar Q4 2026 | +10.2% | — | Rithm highlights servicing, inflows and technology-led efficiency |
| CBRE CBRE Group, Inc. | FY2026 Q3 · Calendar Q4 2026 | +4.6% | -2.5% | CBRE: Infrastructure Growth Offsets Capital-Markets Headwinds |
Latest beats and misses
Who reports nextBeat on EPS
- BAHFY2027 Q2 · October 23, 2026+18.9% EPS-0.3% move
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the WELL recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-27T00:10:41.412145+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-27T00:10:41.409272+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-27. For educational purposes only; not investment advice.